Drug Price Controls Threaten Cancer Cures

Health Depositphotos 5734409 l 2015

The IRA’s price controls may indeed save the federal government some money in the short term. But their long-term impact on medical research will be devastating. Treatments that could prevent suffering or death — that could end cancer as we know it — could go undiscovered, to the detriment of patients today and tomorrow.

A federal judge in New Jersey recently dismissed a lawsuit seeking to strike down the Inflation Reduction Act’s program of price controls for prescription drugs dispensed through Medicare. It was the fifth suit of its kind to fail this year.

Democrats have cheered the IRA’s price controls for supposedly making drugs more accessible to seniors. But they have an insidious downside. By slowing the pace of new drug innovation, price controls will seriously harm Americans with cancer now and in the future.

Read the entire op-ed in Townhall.com.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top